Reconstruction and Exploratory Analysis of mTORC1 Signaling Pathway and Its Applications to Various Diseases Using Network-Based Approach |
Buddham, Richa
(Centre for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University)
Chauhan, Sweety (Centre for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University) Narad, Priyanka (Centre for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University) Mathur, Puniti (Centre for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University) |
1 | Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14: 1296-1302. DOI |
2 | Peter Kovacs, Robert L Hanson, Yong-Ho Lee, Xiaolin Yang, Sayuko Kobes, Paska A Permana, et al. 2003. The role of insulin receptor substrate-1 Gene (IRS1) in type 2 diabetes in pima Indians. Diabetes 52: 3005-3009. DOI |
3 | Kremenevskaja N, Wasielewski RV, Rao AS, Schofl C, Andersson T, Brabant G. 2005. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene. 24: 2144-2154. DOI |
4 | Cheruku HR, Mohamedali A, Cantor DI, HweeTan S, Nice EC, Baker MS. 2015. Transforming growth factor-β, MAPK and Wnt signaling interactions in cancer. EuPA Open Proteomics. 8: 104-115. DOI |
5 | Sanders SS, De Simone FI, Thomas GM. 2019. mTORC1 signaling is palmitoylation-dependent in hippocampal neurons and nonneuronal cells and involves dynamic palmitoylation of LAMTOR1 and mTOR. Front. Cell Neurosci. 13: 115-130. DOI |
6 | Abramowicz A, Gos M. 2014.Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev. Period Med. 18: 297-306. |
7 | Cardamom GA, Gonzalez N, Maggio J, Lorenzano PM, Gomez DE. 2017. Rho GTPase as therapeutic targets in cancer. Int. J. Oncol. 51: 1025-1034. DOI |
8 | Popova NV, Jucker M. 2021.The Role of mTOR signaling as a therapeutic target in cancer. Int. J. Mol. Sci. 22: 1743-1760. DOI |
9 | Glaab E, Baudot A, Krasnogor N, Schneider R, Valencia A. 2012. Enrich Net: network-based gene set enrichment analysis. Bioinformatics 28: i451-i457. DOI |
10 | Hietakangas V, Cohen SM. 2008. TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. BMC Cancer 8: 282-289. DOI |
11 | Mao Z, Zhang W. 2018. Role of mTOR in glucose and lipid metabolism. Int. J. Mol. Sci. 19: 2043-2057. DOI |
12 | Michal Grzmil, Pier Morin Jr, Maria Maddalena Lino, Adrian Merlo, Stephan Frank, Yuhua Wang, et al. 2011. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. Cancer Res. 71: 2392-2402. DOI |
13 | Jaime Miguel Pita , Ines Filipa Figueiredo, Margarida Maria Moura, Valeriano Leite, Branca Maria Cavaco. 2014. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99: E497-E507. DOI |
14 | Clark TG, Bradburn MJ, Love SB, Altman DG. 2003. Survival analysis part I: basic concepts and first analyses. Br. J. Cancer 89: 232-238. DOI |
15 | Inoki K, Li Y, Xu T, Guan KL. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17: 1829-1834. DOI |
16 | Greer EL, Brunet A. 2005. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425. DOI |
17 | Yang J, Nie J, Ma XL, Wei Y, Peng Y, Wei X. 2019. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol. Cancer 18: 26. DOI |
18 | Peter WS. 2017. Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J. Natl. Cancer Inst. 109: djx071-djx089. |
19 | Wolfson RL, Chantranupong L, Wyant GA, Gu X, Orozco JM, Shen K, et al. 2017. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature 543: 438-442. DOI |
20 | Gregor Warsow, Boris Greber, Steffi S I Falk, Clemens Harder, Marcin Siatkowski, Sandra Schordan, et al. 2010. ExprEssence - Revealing the essence of differential experimental data in the context of an interaction/regulation net-work. BMC Syst. Biol. 4: 164-182. DOI |
21 | Maryam S, Funda MB. 2019. Targeting AKT for cancer therapy. Expert. Opin. Investig. Drugs 28: 977-988. DOI |
22 | Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643. DOI |
23 | Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S, et al. 2012.PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12. Nat. Cell Biol. 14: 686-696. DOI |
24 | Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. DOI |
25 | Garcia-Martinez JM, Alessi DR. 2008. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid -induced protein kinase 1 (SGK1). Biochem. J. 416: 375-385. DOI |
26 | Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. 2014. A diverse array of cancer -associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 4: 554-563. DOI |
27 | Porta C, Amici MD, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. 2008. Circulating interleukin-6 as a tumor marker for Hepatocellular carcinoma. Ann. Oncol. 19: 353-358. DOI |
28 | Bo Li, Zhang J, Su Y, Hou Y, Wang Z. 2019.Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism. Mol. Med. Rep. 20: 3793-3801. |
29 | Ramirez Reyes JMJ, Cuesta R, Pause A. 2021. Folliculin: a regulator of transcription through AMPK and mTOR signaling pathways. Front. Cell Dev. Biol. 9: 667311-667333. DOI |
30 | Guo Y, Xiao Z, Yang Li, Gao Y, Zhu QJ, Hu LJ. 2020. Hypoxia inducible factors in Hepatocellular carcinoma. Oncotarget 43: 3-15. |
31 | Dietrich P, Gaza A, Wormser L. 2019. Neuroblastoma RAS viral oncogene homolog (NRAS) is a novel prognostic marker and contributes to sorafenib resistance in Hepatocellular Carcinoma. Neoplasia 21: 257-268. DOI |
32 | Rodrigues C, Leanna R Joy, Sasikala P Sachithanandan, Sudhir Krishna. 2019. Notch signaling in cervical cancer. Exp. Cell Res. 385: 111682-111699. DOI |
33 | Winterhalter C, Widera P, Krasnogor N. 2014. JEPETTO: a Cytoscape plugin for gene set enrichment and topological analysis based on interaction networks. Bioinformatics 30: 1029-1037. DOI |
34 | Wang HY, Lian P, Zheng PS. 2015. SOX9, a potential tumor suppressor in cervical cancer, transactivate p21WAF1/CIP1 and suppresses cervical tumor growth. Oncotarget. 6: 20711-20722. DOI |
35 | Fernandes Silva GA, Lima Nunes RA, Morale MG, Boccardo E, Aguayo F, Termini L, et al. 2018. Oxidative stress: therapeutic approaches for cervical cancer treatment. Clinics (Sao Paulo). 73: e548s-e558s. DOI |
36 | Atkinson GP, Nozell SE, Benveniste ET. 2010. NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Rev. Neurother. 10: 575-586. DOI |
37 | Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6: 1122-1128. DOI |
38 | McCall MN, Bolstad BM, Irizarry RA. 2010. Frozen robust multiarray analysis (fRMA). Biostatistics 11: 242-253. DOI |
39 | Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13: 2498-2504. DOI |
40 | Maere S, Heymans K, Kuiper M. 2005. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21: 3448-3449. DOI |
41 | Glaab E, Baudot A, Krasnogor N, Valencia A. 2010. Extending pathways and processes using molecular interaction networks to analyze cancer genome data. BMC Bioinformatics 11: 597-607. DOI |
42 | Bader GD, Hogue CW. 2003. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4: 2849-2861. |
43 | Buller V, Carolyn L. 2010. Role of GLUT1 in the Mammalian target of rapamycin pathway: mechanisms of regulation. Mlibrary 34: 23-43. |
44 | Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. 2008. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8: 224-236. DOI |
45 | Magdalena K, Cynthia SS, Tasha M, Hong Wu, Elizabeth PH. 2008. mTOR is activated in the majority of malignant melanomas. J. Investig. Dermatol. 128: 980-987. DOI |
46 | Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, et al. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189. DOI |
47 | Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell. 25: 903-915. DOI |
48 | Holz MK, Ballif BA, Gygi SP, Blenis J. 2005. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123: 569- 580. DOI |
49 | Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, et al. 1999. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13: 1422-1437. DOI |
50 | Justin TA, Ruowen Z, Rebecca JB.2021. GLI1: A therapeutic target for cancer. Front. Oncol. 11: 673154. DOI |
51 | Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, et al. 2015. Differential regulation of mTORC1 by leucine and glutamine. Science 347: 194-198. DOI |
52 | Cristina R, Rossella E. 2021. A narrative review of genetic alterations in primary thyroid epithelial cancer. Int. J. Mol. Sci. 22: 1726-1738. DOI |
53 | Joanne ES, Noon G. 2020. The impact of autophagy during the development and survival of glioblastoma. Open Biol. 10: 200184-200198. DOI |
54 | Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. 2016. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351: 728-733. DOI |
55 | Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13: 1259-1268. DOI |
56 | Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. 2005. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15: 702-713. DOI |
57 | Mohammed Altaf, Janakiram NB, Madka Venkateshwar, et al. 2014. Eflornithine (DFMO) Prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Cancer Prev. Res. (Phila). 7: 1198-1209. DOI |
58 | Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175. DOI |
59 | Saxton RA, Sabatini DM. 2017. mTOR Signaling in growth, metabolism, and disease. Cell 168: 361-371. DOI |
60 | Eng CP, Sehgal SN, Vezina C.1984. Activity of rapamycin (AY-22, 989) against transplanted tumors. J. Antibiot. (Tokyo) 37: 1231-1247. DOI |
61 | Huang Q, Li JH, Zheng J, and Wei A. 2019. The carcinogenic role of the notch signaling pathway in the development of hepatocellular carcinoma. J. Cancer 10: 1570-1579. DOI |
62 | Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. 2013. A Tumor suppressor complex with GAP activity for the Rag GTPase that signal amino acid sufficiency to mTORC1. Science 340: 1100-1126. DOI |
63 | Hongxi Chen, Zhipeng Zhang, Yebin Lu, Kun Song, Xiwu Liu, Fada Xia, et al. 2017. Down-regulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells. Cancer Sci. 108: 1811-1819. DOI |